Tailoring to RB: tumour suppressor status and therapeutic response

[1]  Lajos Pusztai,et al.  Gene expression profiling of breast cancer , 2009, Breast Cancer Research.

[2]  F. McCormick,et al.  E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines , 2008, Oncogene.

[3]  G. Mazzini,et al.  Loss of Retinoblastoma Tumor Suppressor Protein Makes Human Breast Cancer Cells More Sensitive to Antimetabolite Exposure , 2008, Clinical Cancer Research.

[4]  R. Greil,et al.  Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.

[5]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Blais,et al.  E2F-associated chromatin modifiers and cell cycle control. , 2007, Current opinion in cell biology.

[7]  J. Lees,et al.  Life and death decisions by the E2F transcription factors. , 2007, Current opinion in cell biology.

[8]  Karla Kerlikowske,et al.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.

[9]  M. Dyer,et al.  Targeting MDM2 and MDMX in retinoblastoma. , 2007, Current cancer drug targets.

[10]  C. Cordon-Cardo,et al.  Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1 , 2007, The EMBO journal.

[11]  B. Aronow,et al.  Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function , 2007, Oncogene.

[12]  S. Thorgeirsson,et al.  RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. , 2007, Gastroenterology.

[13]  E. Knudsen,et al.  Retinoblastoma deficiency increases chemosensitivity in lung cancer. , 2007, Cancer research.

[14]  A. Turrisi,et al.  Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[15]  Aleksandra M. Michalowska,et al.  Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. , 2007, Cancer research.

[16]  J. Zucman‐Rossi,et al.  Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. , 2007, Pharmacogenomics.

[17]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[18]  D. Grignon,et al.  Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Knudsen,et al.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. , 2007, Cancer research.

[20]  L. Montanaro,et al.  Controversial relationship between the expression of the RB pathway components and RB protein phosphorylation in human breast cancer. , 2007, Histology and histopathology.

[21]  S. Paik.  Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.

[22]  M. Gleave,et al.  Therapeutic options in advanced prostate cancer: Present and future , 2007, Current urology reports.

[23]  G. Martinelli,et al.  Relationship between the RB1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome. , 2007, Histology and histopathology.

[24]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Knudsen,et al.  Impact of differential cyclin D1 expression and localisation in prostate cancer , 2007, British Journal of Cancer.

[26]  E. Knudsen,et al.  RB in Breast Cancer: The Crossroads of Tumorigenesis and Treatment , 2007, Cell cycle.

[27]  I. Ellis,et al.  A gene-expression signature to predict survival in breast cancer across independent data sets , 2007, Oncogene.

[28]  M. Tucker,et al.  Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. , 2007, Journal of the National Cancer Institute.

[29]  S. Lowe,et al.  The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. , 2007, The Journal of clinical investigation.

[30]  Jean Y. J. Wang,et al.  Separation of Anti-Proliferation and Anti-Apoptotic Functions of Retinoblastoma Protein through Targeted Mutations of Its A/B Domain , 2006, PloS one.

[31]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[33]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[34]  Jun-Yuan Ji,et al.  Functional Identification of Api5 as a Suppressor of E2F-Dependent Apoptosis In Vivo , 2006, PLoS genetics.

[35]  P. Lipponen,et al.  Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. , 2006, Anticancer research.

[36]  E. Knudsen,et al.  Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. , 2006, Current molecular medicine.

[37]  David G Johnson,et al.  Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. , 2006, Current molecular medicine.

[38]  David G Johnson,et al.  Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.

[39]  J. Herman,et al.  Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 , 2006, Oncogene.

[40]  Jiaoti Huang,et al.  Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression , 2006, Modern Pathology.

[41]  K. Keyomarsi,et al.  The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein. , 2006, Cancer research.

[42]  Christine Desmedt,et al.  Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer , 2006, Cell cycle.

[43]  N. Dyson,et al.  A Gradient of Epidermal Growth Factor Receptor Signaling Determines the Sensitivity of rbf1 Mutant Cells to E2F-Dependent Apoptosis , 2006, Molecular and Cellular Biology.

[44]  A. Hjerpe,et al.  Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. , 2006, International journal of oncology.

[45]  D. Cobrinik,et al.  Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. , 2006, Archives of ophthalmology.

[46]  G. Peters,et al.  Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all , 2006, Nature Reviews Molecular Cell Biology.

[47]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[48]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Kenneth N Ross,et al.  Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. , 2006, Cancer research.

[50]  K. Knudsen.  The cyclin D1b splice variant: an old oncogene learns new tricks , 2006, Cell Division.

[51]  H. Döhner,et al.  Cytogenetics and molecular cytogenetics in multiple myeloma. , 2006, European journal of cancer.

[52]  J. Zucman‐Rossi,et al.  Genetics of hepatocellular tumors , 2006, Oncogene.

[53]  Zhiyuan Hu,et al.  Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.

[54]  F. Anschau,et al.  p16INK4A expression in cervical premalignant and malignant lesions. , 2006, Experimental and molecular pathology.

[55]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[56]  S. Thorgeirsson,et al.  Molecular prognostication of liver cancer: end of the beginning. , 2006, Journal of hepatology.

[57]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[58]  J. Paramio,et al.  Is the Loss of pRb Essential for the Mouse Skin , 2006, Cell cycle.

[59]  Cornelius Diamond,et al.  A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[61]  E. Villa-Moruzzi,et al.  Direct interaction between the catalytic subunit of Protein Phosphatase 1 and pRb , 2006, Cancer Cell International.

[62]  K. Wikenheiser-Brokamp.  Retinoblastoma family proteins: insights gained through genetic manipulation of mice , 2006, Cellular and Molecular Life Sciences CMLS.

[63]  M. Schumacher,et al.  Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients , 2006, Clinical Cancer Research.

[64]  J. Diehl,et al.  Location, location, location: The role of cyclin D1 nuclear localization in cancer , 2005, Journal of cellular biochemistry.

[65]  J. Fletcher,et al.  Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. , 2005, American journal of clinical pathology.

[66]  C P Neal,et al.  Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.

[67]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[68]  F. Dick,et al.  Examination of the pRb-Dependent and pRb-Independent Functions of E7 In Vivo , 2005, Journal of Virology.

[69]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[70]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[71]  G. Kay,et al.  Melanocytes in conditional Rb-/- mice are normal in vivo but exhibit proliferation and pigmentation defects in vitro. , 2005, Pigment cell research.

[72]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G. Babcock,et al.  Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. , 2005, Cancer research.

[74]  N. Dyson,et al.  The E2F transcriptional network: old acquaintances with new faces , 2005, Oncogene.

[75]  D. Cobrinik.  Pocket proteins and cell cycle control , 2005, Oncogene.

[76]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[77]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[78]  L. Akslen,et al.  Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. , 2004, International journal of oncology.

[79]  S. Thorgeirsson,et al.  Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. , 2004, Gastroenterology.

[80]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[81]  A. Blais,et al.  Hitting their targets: an emerging picture of E2F and cell cycle control. , 2004, Current opinion in genetics & development.

[82]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[83]  K. Wikenheiser-Brokamp.  Rb family proteins differentially regulate distinct cell lineages during epithelial development , 2004, Development.

[84]  A Coldman,et al.  Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers , 2004, The Journal of pathology.

[85]  S. Steinberg,et al.  Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[86]  T. Jacks,et al.  Cell type-specific effects of Rb deletion in the murine retina. , 2004, Genes & development.

[87]  H. A. Rogoff,et al.  Life, Death, and E2F: Linking Proliferation Control and DNA Damage Signaling via E2F1 , 2004, Cell cycle.

[88]  S. Lowe,et al.  Reversing Drug Resistance In Vivo , 2004, Cell cycle.

[89]  R. Slack,et al.  Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. , 2004, Cancer cell.

[90]  T. Jacks,et al.  Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents , 2004, Oncogene.

[91]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[92]  M. Anzola,et al.  p16 INK4A Gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy , 2004, Journal of gastroenterology and hepatology.

[93]  K. Kristiansen,et al.  Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[94]  S. Groshen,et al.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  F. Kaye,et al.  For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. , 2004, Journal of the National Cancer Institute.

[96]  B. Spike,et al.  New roles for the RB tumor suppressor protein. , 2004, Current opinion in genetics & development.

[97]  T. Jacks,et al.  RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. , 2004, Nucleic acids research.

[98]  T. Jacks,et al.  Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In Vivo , 2003, Molecular and Cellular Biology.

[99]  Kristian Helin,et al.  Identification of Target Genes of the p16INK4A-pRB-E2F Pathway* , 2003, Journal of Biological Chemistry.

[100]  W. ElShamy,et al.  Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. , 2003, Molecular cell.

[101]  A. Berns,et al.  Rb and p107 are required for normal cerebellar development and granule cell survival but not for Purkinje cell persistence , 2003, Development.

[102]  J. Alsner,et al.  Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer , 2003, British Journal of Cancer.

[103]  T. Jacks,et al.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry , 2003, Nature.

[104]  A. Flesken-Nikitin,et al.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.

[105]  M. West,et al.  Distinct gene expression phenotypes of cells lacking Rb and Rb family members. , 2003, Cancer research.

[106]  S. Lowe,et al.  Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence , 2003, Cell.

[107]  William C Hahn,et al.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.

[108]  Jean Y. J. Wang,et al.  Coordinated regulation of life and death by RB , 2003, Nature Reviews Cancer.

[109]  K. Tsai,et al.  ARF mutation accelerates pituitary tumor development in Rb+/− mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[110]  E. Harlow,et al.  The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.

[111]  N. Dyson,et al.  A revised picture of the E2F transcriptional network and RB function. , 2002, Current opinion in cell biology.

[112]  C. Marshall,et al.  Loss of Rb overrides the requirement for ERK activity for cell proliferation , 2002, Journal of Cell Science.

[113]  J. Carroll,et al.  Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. , 2002, Cancer research.

[114]  D. Heisey,et al.  Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. , 2002, Cancer letters.

[115]  Steven P. Angus,et al.  Retinoblastoma Tumor Suppressor Targets dNTP Metabolism to Regulate DNA Replication* , 2002, The Journal of Biological Chemistry.

[116]  Matthew W. Strobeck,et al.  Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. , 2002, Cancer research.

[117]  Ramana V. Davuluri,et al.  Direct coupling of the cell cycle and cell death machinery by E2F , 2002, Nature Cell Biology.

[118]  S. Mittnacht,et al.  RB activation defect in tumor cell lines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[119]  F. Kaye,et al.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.

[120]  M. J. Tevethia,et al.  Simian Virus 40 Large T Antigen and Two Independent T-Antigen Segments Sensitize Cells to Apoptosis following Genotoxic Damage , 2002, Journal of Virology.

[121]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[122]  U. Brinck,et al.  Downregulation of the Retinoblastoma Gene Expression in the Progression of Malignant Melanoma , 2002, Pathobiology.

[123]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[124]  H. McLeod,et al.  Analysis of key cell‐cycle checkpoint proteins in colorectal tumours , 2002, The Journal of pathology.

[125]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[126]  K. Münger.  The role of human papillomaviruses in human cancers. , 2002, Frontiers in bioscience : a journal and virtual library.

[127]  A. Cittadini,et al.  Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle‐associated proteins, cell proliferation and clinical outcome , 2002, International journal of cancer.

[128]  J. Diehl.  Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.

[129]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[130]  K. Tsai,et al.  ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos , 2002, Current Biology.

[131]  K. Knudsen,et al.  Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity* , 2002, The Journal of Biological Chemistry.

[132]  T. Volkert,et al.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. , 2002, Genes & development.

[133]  A. Ziegler,et al.  p16INK4a is a Prognostic Marker in Resected Ductal Pancreatic Cancer: An Analysis of p16INK4a, p53, MDM2, an Rb , 2002, Annals of surgery.

[134]  M. Blasco,et al.  Putting the stress on senescence. , 2001, Current opinion in cell biology.

[135]  J. Nikliński,et al.  Prognostic molecular markers in non-small cell lung cancer. , 2001, Lung cancer.

[136]  Karl Münger,et al.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein , 2001, Oncogene.

[137]  R. Spang,et al.  Role for E2F in Control of Both DNA Replication and Mitotic Functions as Revealed from DNA Microarray Analysis , 2001, Molecular and Cellular Biology.

[138]  Rei Takahashi,et al.  Disruption of the p16/Cyclin D1/Retinoblastoma Protein Pathway in the Majority of Human Hepatocellular Carcinomas , 2001, Oncology.

[139]  O. Jänne,et al.  Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. , 2001, Molecular endocrinology.

[140]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[141]  Antonin Bukovsky,et al.  Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function , 2001, Molecular and Cellular Biology.

[142]  J. Herman,et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  D. Neal,et al.  Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67 , 2001, British Journal of Cancer.

[144]  James D. Evans,et al.  K‐ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF‐1, cyclin D1, erbB‐2 and erbB‐3 in resected pancreatic ductal adenocarcinoma , 2000, International journal of cancer.

[145]  L. Akslen,et al.  Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. , 2000, Anticancer research.

[146]  I. Bièche,et al.  Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer , 2000, Molecular carcinogenesis.

[147]  H. J. Kim,et al.  Abrogation of the p16-Rb pathway in Korean hepatocellular carcinomas. , 2000, Hepato-gastroenterology.

[148]  K. Knudsen,et al.  RB-Dependent S-Phase Response to DNA Damage , 2000, Molecular and Cellular Biology.

[149]  J. McKay,et al.  Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.

[150]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.

[151]  H. Varma,et al.  Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain , 2000, Oncogene.

[152]  D. Aust,et al.  FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy , 2000, Laboratory Investigation.

[153]  R. Bernards,et al.  Distinct Initiation and Maintenance Mechanisms Cooperate to Induce G1 Cell Cycle Arrest in Response to DNA Damage , 2000, Cell.

[154]  R. Blamey,et al.  INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[155]  Matthew W. Strobeck,et al.  Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[156]  L. Akslen,et al.  Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[157]  C. Cordon-Cardo,et al.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[158]  P. May,et al.  Cell cycle control and cancer. , 2000, Pathologie-biologie.

[159]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[160]  A. Scharl,et al.  Expression of p16 and lack of pRB in primary small cell lung cancer , 1999, The Journal of pathology.

[161]  K. Keyomarsi,et al.  UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent , 1999, Oncogene.

[162]  J. Harbour,et al.  Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.

[163]  E. Gelmann,et al.  RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[164]  G. Landberg,et al.  G1‐S transition defects occur in most breast cancers and predict outcome , 1999, Breast Cancer Research and Treatment.

[165]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[166]  W. Cavenee,et al.  D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. , 1999, Cancer research.

[167]  A. Lassar,et al.  pRb is required for MEF2-dependent gene expression as well as cell-cycle arrest during skeletal muscle differentiation , 1999, Current Biology.

[168]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[169]  S. Pileri,et al.  Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. , 1998, Journal of clinical pathology.

[170]  N. Dyson,et al.  pRB plays an essential role in cell cycle arrest induced by DNA damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[171]  W. Cavenee,et al.  Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[172]  S. Gansauge,et al.  Prognostic significance of molecular alterations in human pancreatic carcinoma – an immunohistological study , 1998, Langenbeck's Archives of Surgery.

[173]  T. Jacks,et al.  Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/−) mice , 1998, Nature Genetics.

[174]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[175]  Philip Smith,et al.  Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters , 1998, International journal of cancer.

[176]  S. Mittnacht,et al.  Control of pRB phosphorylation. , 1998, Current opinion in genetics & development.

[177]  Robert A. Weinberg,et al.  Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.

[178]  R. deVere White,et al.  Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade , 1998, The Prostate.

[179]  C. Larsson,et al.  Identification of two distinct deleted regions on chromosome 13 in prostate cancer , 1998, Oncogene.

[180]  S. Srivastava,et al.  Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.

[181]  L. Akslen,et al.  Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma , 1997, International journal of cancer.

[182]  J. Melamed,et al.  Allelic loss on chromosome 13q in human prostate carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[183]  J. Wang,et al.  Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation , 1997, Molecular and cellular biology.

[184]  K. Ohtsubo,et al.  Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[185]  C. Sheehan,et al.  The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma , 1997, Cancer.

[186]  B. Gallie.  Predictive testing for retinoblastoma comes of age. , 1997, American journal of human genetics.

[187]  S. Gansauge,et al.  Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. , 1997, Cancer research.

[188]  M. Ewen,et al.  Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein , 1997, Nature.

[189]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[190]  J. Moul,et al.  Mutations of the p16 gene product are rare in prostate cancer , 1997, The Prostate.

[191]  R. Weinberg,et al.  TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. , 1996, Molecular biology of the cell.

[192]  B. Angus,et al.  RETINOBLASTOMA PROTEIN IN HUMAN BREAST CARCINOMA: IMMUNOHISTOCHEMICAL STUDY USING A NEW MONOCLONAL ANTIBODY EFFECTIVE ON ROUTINELY PROCESSED TISSUES , 1996, The Journal of pathology.

[193]  D. Niewoehner,et al.  Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.

[194]  R. Weinberg,et al.  Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts , 1996, Molecular and cellular biology.

[195]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[196]  Robert L. Sutherland,et al.  Cyclins and Breast Cancer , 1996, Journal of Mammary Gland Biology and Neoplasia.

[197]  K. Cooney,et al.  Distinct regions of allelic loss on 13q in prostate cancer. , 1996, Cancer research.

[198]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[199]  Q. Dou,et al.  Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[200]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[201]  R. Weinberg,et al.  Growth suppression by p16ink4 requires functional retinoblastoma protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[202]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[203]  G. Wahl,et al.  Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[204]  S. Steinberg,et al.  Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.

[205]  J. Bartek,et al.  Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.

[206]  P. Hinds.  The retinoblastoma tumor suppressor protein. , 1995, Current opinion in genetics & development.

[207]  J. Brooks,et al.  Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas , 1995, The Prostate.

[208]  J. Neoptolemos,et al.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. , 1994, British Journal of Cancer.

[209]  W. Kaelin,et al.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[210]  A. Berns,et al.  Developmental rescue of an embryonic‐lethal mutation in the retinoblastoma gene in chimeric mice. , 1994, The EMBO journal.

[211]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[212]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[213]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[214]  W. Lee,et al.  The transcription factor E2F-1 mediates the autoregulation of RB gene expression , 1994, Molecular and cellular biology.

[215]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[216]  R. Weinberg,et al.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins , 1992, Cell.

[217]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[218]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[219]  B. Gallie,et al.  Genetic origin of mutations predisposing to retinoblastoma. , 1985, Science.

[220]  T. P. Dryja,et al.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma , 1983, Nature.

[221]  C. Desmedt,et al.  Predicting risk of breast cancer recurrence using gene-expression profiling. , 2007, Pharmacogenomics.

[222]  Steven P. Angus,et al.  Analysis of RB action in DNA damage checkpoint response. , 2004, Methods in molecular biology.

[223]  R. Sutherland,et al.  Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells , 2004, Breast Cancer Research and Treatment.

[224]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[225]  D. Barnes,et al.  Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.

[226]  M. Barbacid,et al.  Driving the cell cycle to cancer. , 2003, Advances in experimental medicine and biology.

[227]  Sehwan Han,et al.  Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. , 2003, Oncology reports.

[228]  M. Barbacid,et al.  To Cycle or Not to Cycle: a Critical Decision in Cancer , 2022 .

[229]  N. Dyson,et al.  Retinoblastoma protein partners. , 2001, Advances in cancer research.

[230]  V. N. Nguyen,et al.  Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. , 2000, Acta histochemica.

[231]  E. Rubin,et al.  Role of pRB dephosphorylation in cell cycle regulation. , 2000, Frontiers in bioscience : a journal and virtual library.

[232]  J. Mohler,et al.  Overexpression of cyclin D1 is rare in human prostate carcinoma , 1999, The Prostate.

[233]  Chen,et al.  UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent , 1999, Oncogene.

[234]  B. Czerniak,et al.  Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. , 1997, International journal of radiation oncology, biology, physics.

[235]  N. Shepherd,et al.  p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? , 1997, British Journal of Cancer.

[236]  M. Ittmann,et al.  Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. , 1996, Human pathology.

[237]  G. Peters,et al.  Perturbation of cell cycle regulators in human cancer. , 1996, Cancer surveys.

[238]  V. Kosma,et al.  Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. , 1995, European journal of cancer.

[239]  S. Thorgeirsson,et al.  Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. , 1994, Cancer research.

[240]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[241]  K. Knudsen,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas AR, the cell cycle, and prostate cancer , 2022 .